US · QTTB · BIOTECHNOLOGY
Q32 Bio Inc. (QTTB) intrinsic value and stock valuation
$8.34as of 2026-11-21 · Mkt cap 199.31M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Q32 Bio Inc. DCF and intrinsic value
InvestorsCraft values QTTB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from QTTB’s statements →
Q32 Bio Inc. Graham Number
Graham Number: $13.65d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $53.7M | $0.00 | -$-6.65M | $3.21M | $34M |
| Operating income | $16.9M | -$-66.1M | -$-48.26M | -$-39.23M | -$-95.95M |
| Net income | $29.8M | -$-47.73M | -$-53.74M | -$-42.81M | -$-95.76M |
| EPSd | $2.42M | -$-3.91M | -$-16.69M | -$-13.42M | -$-31.19M |
| Operating cash flow | -$-33.54M | -$-67.72M | -$-18.68M | -$-10.96M | -$-109.75M |
| Capital expenditure | $0.00 | -$-70K | -$-10K | -$-2.48M | -$-2.4M |
| Free cash flow | -$-33.54M | -$-67.79M | -$-18.68M | -$-13.44M | -$-112.15M |
| Total assets | $61.8M | $92.3M | $47.1M | $61.8M | $211.7M |
| Total debt | $15.3M | $18.9M | $50.8M | $44.7M | $23.9M |
| Net debt | -$-32.95M | -$-59.06M | $25.2M | $840K | -$-84.45M |
| Total equity | $42M | $5.67M | -$-182.92M | -$-130.71M | $169.7M |
| Cash and short-term investments | $48.3M | $78M | $25.6M | $43.9M | $155.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $53.7M | $0.00 | -$-6.65M | $3.21M | $34M |
| Cost of revenue | $390K | $490K | $500K | $2.6M | $9.54M |
| Gross profit | $53.4M | -$-490K | -$-7.15M | $610K | $24.4M |
| Research and development expenses | $19.2M | $48.1M | $31.7M | $35.8M | $93.1M |
| Selling, general and administrative expenses | $17.7M | $18M | $9.88M | $10.1M | $6.76M |
| Other expenses | -$-390K | -$-490K | -$-500K | $0.00 | $20.5M |
| Operating expenses | $36.4M | $65.6M | $41.1M | $45.9M | $120.4M |
| Cost and expenses | $36.8M | $66.1M | $41.6M | $45.9M | $129.9M |
| Interest income | $2.2M | $3.9M | $0.00 | $3.23M | $180K |
| Interest expense | $1.1M | $300K | $1.5M | $0.00 | $0.00 |
| Depreciation and amortization | $390K | $490K | $500K | $370K | $9.54M |
| Ebitda | $31.3M | -$-45.3M | -$-47.76M | -$-38.85M | -$-86.22M |
| Operating income | $16.9M | -$-66.1M | -$-48.26M | -$-39.23M | -$-95.95M |
| Total other income/expenses, net | $12.9M | $18.4M | -$-5.17M | -$-3.52M | $180K |
| Income before tax | $29.8M | -$-47.71M | -$-53.42M | -$-42.75M | -$-95.76M |
| Income tax expense | $0.00 | $20K | $320K | $60K | $0.00 |
| Net income | $29.8M | -$-47.73M | -$-53.74M | -$-42.81M | -$-95.76M |
| Weighted average shares outstanding | $12.3M | $12.2M | $3.22M | $3.19M | $3.07M |
| Weighted average diluted shares outstanding | $12.3M | $12.2M | $3.22M | $3.19M | $3.07M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $48.3M | $78M | $25.6M | $43.9M | $155.9M |
| Net receivables | $0.00 | $560K | $760K | $1.06M | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $1.75M | $0.00 |
| Total current assets | $55.1M | $81.9M | $28.7M | $46.9M | $191.9M |
| Property, plant and equipment, net | $6.08M | $7.09M | $8.08M | $9.17M | $17.9M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $650K | $2.6M | $5.65M | $25.8M | $1.95M |
| Total non-current assets | $6.73M | $10.5M | $18.3M | $14.9M | $19.8M |
| Total assets | $61.8M | $92.3M | $47.1M | $61.8M | $211.7M |
| Accounts payable | $880K | $2.99M | $3.47M | $1.44M | $2.37M |
| Short-term debt | $6.93M | $3.71M | $1.42M | $32.9M | $250K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $14.5M | $3.21M |
| Total current liabilities | $11.4M | $16.5M | $14.1M | $57.9M | $17.2M |
| Long-term debt | $8.42M | $15.2M | $49.4M | $11.9M | $23.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $11.3M | $1.16M |
| Total non-current liabilities | $8.42M | $70.2M | $215.9M | $134.6M | $24.8M |
| Capital lease obligations | $4.94M | $6.25M | $6.79M | $7.26M | $23.7M |
| Total liabilities | $19.8M | $86.7M | $230M | $192.5M | $42.1M |
| Common stock | $0.00 | $0.00 | $0.00 | $10K | $10K |
| Retained earnings | -$-204.99M | -$-234.81M | -$-187.08M | -$-429.14M | -$-424.13M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | -$-400K | -$-10K |
| Total equity | $42M | $5.67M | -$-182.92M | -$-130.71M | $169.7M |
| Total investments | $650K | $2.6M | $5.65M | $25.8M | $49.4M |
| Total debt | $15.3M | $18.9M | $50.8M | $44.7M | $23.9M |
| Net debt | -$-32.95M | -$-59.06M | $25.2M | $840K | -$-84.45M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $29.8M | -$-47.73M | -$-53.74M | -$-42.81M | -$-95.76M |
| Depreciation and amortization | $390K | $490K | $500K | $370K | $9.54M |
| Stock-based compensation | $5.25M | $4.39M | $1.43M | $1.24M | $0.00 |
| Change in working capital | -$-4.04M | -$-9.64M | $26.3M | $26.9M | -$-41.8M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-2.11M | -$-1.04M | $2.03M | -$-1.24M | -$-2.49M |
| Net cash provided by operating activities | -$-33.54M | -$-67.72M | -$-18.68M | -$-10.96M | -$-109.75M |
| Investments in property, plant and equipment | $0.00 | -$-70K | -$-10K | -$-2.48M | -$-2.4M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $130M | $0.00 |
| Net cash used for investing activities | $7M | $19.9M | -$-10K | -$-2.47M | -$-50.79M |
| Common stock issued | $0.00 | $42M | $110K | $70K | $52.2M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-3.12M | $95.1M | $410K | $30.1M | $52.2M |
| Net change in cash | -$-29.67M | $47.4M | -$-8.37M | $16.7M | -$-109.05M |
| Cash at end of period | $48.9M | $78.6M | $25.6M | $49.5M | $108.4M |
| Operating cash flow | -$-33.54M | -$-67.72M | -$-18.68M | -$-10.96M | -$-109.75M |
| Capital expenditure | $0.00 | -$-70K | -$-10K | -$-2.48M | -$-2.4M |
| Free cash flow | -$-33.54M | -$-67.79M | -$-18.68M | -$-13.44M | -$-112.15M |
Line items
Line items
Line items
About Q32 Bio Inc.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
- CEO
- Jodie Pope Morrison
- Employees
- 22
- Beta
- -0.33
Explore
Frequently asked questions
What is the intrinsic value of Q32 Bio Inc. (QTTB)?
InvestorsCraft does not currently publish an intrinsic value for QTTB. How the IC value is calculated.
Is QTTB undervalued?
InvestorsCraft does not publish an undervaluation signal for QTTB at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.